Unknown statusInterventionalPhase 4Last updated Jul 9, 2012

RAAS Inhibitor Drugs in Dialysis Patients

Upstream Use of Aliskiren in Hypertensive Haemodialysis Patients: Effects on Cardiovascular Outcomes

Overview

ClinicalTrials.gov ID: NCT01635387
Lead Sponsor: University of Campania Luigi VanvitelliOTHER
Brief Summary: Hypertensive haemodialysis patients are at high risk for cardiovascular events. This study was undertaken to ascertain whether the upstream of aliskirne, a direct renin inhibitor improves mortality and cardiovascular outcomes in these high-risk population.
Study Type: Interventional

Status

Study Record Dates

NCT01394770Unknown status

Aliskiren or Amlodipine in Hypertensive Hemodialysed Patients

NCT01318395Completed

Aliskiren on Retinal Vasculature Treatment Study

NCT00518765Completed

Hemodynamic Effects of Aliskiren Compared to Captopril on the Kidney in Healthy Volunteers on a Low- and High- Sodium Diet

NCT00985322Completed

Angiotensin-converting-enzyme (ACE) Inhibitors in Hemodialysis

NCT00549757Terminated

Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases)

NCT01284114Completed

Effects of Aliskiren in Elderly Hypertensive Chronic Kidney Disease (CKD) Patients